Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the tolerability (in terms of drug delivery and
toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely
resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients
will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.